Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides

Mycosis Fungoides Clinical Trial

Official title:

Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05838599
• Other study ID #: AZ10312022
• Status: Recruiting
• Phase: Early Phase 1
• Start date: July 24, 2023
• Est. completion date: February 1, 2026

Study information

• Verified date: March 2024
• Source: Northwestern University
• Contact: Dermatology Clinical Trials Unit
• Phone: 312-503-5944
• Email: NUderm-research[@]northwestern.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Mycosis fungoides (MF) is the most common subtype of cutaneous T cell lymphoma (MF) and presents as cutaneous patches, plaques, and tumors. Radiation therapy (RT) is a frequently pursued management option for CTCL, especially in patients with more advanced skin disease. Imiquimod stimulates a Th1 lymphocyte response with increased IL-2 and IFN-α, but also induces IFN-α, TNF-α, IL-1α, IL-6, and IL-8, thereby bridging both innate and adaptive immunity. Dosing of both radiotherapy (RT) and imiquimod are based on standard-of-care doses/frequencies for CTCL. The reason imiquimod topical is given for a week before giving RT is to prime innate immune activity for when RT is delivered. It is believed that this serves as an adjuvant for the CD8+ antitumor response generated by RT. The primary aim of this study is to assess the safety and efficacy of a combination local radiotherapy and topical imiquimod approach for the treatment of conventional (CD4+) MF.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 25
• Est. completion date: February 1, 2026
• Est. primary completion date: August 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Patients must have confirmed stage IA-IIB mycosis fungoides.
• Patients must be 18-90 years of age.
• Patients must have failed at least one standard therapy for MF.
• Patients must have active, but stable disease for >6 months.
• Patients must have 4 or more discrete MF lesions with at least 2 of them with minimum combined surface area of >50cm2.
• POCBP must have a negative pregnancy test prior to registration on study.
• Patients must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

• Patients who are on current systemic or topical CTCL therapy, unless stable on the treatment for >6 months.
• Patients who have received antibiotic therapy within 4 weeks of study enrollment.
• Patients who are pregnant or nursing. Pregnant people are excluded from this study because IMQ is an agent with potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the gestational parent with IMQ, breastfeeding should be discontinued if the parent is treated with IMQ.
• Patients with psychiatric illness/social situations that would limit compliance with study requirements.

Related Conditions & MeSH terms

• Mycoses
• Mycosis Fungoides

Intervention

Drug:
• Imiquimod
5% cream applied topically 5 days/week for 6 weeks

Radiation:
• Radiation Therapy
2 fractions of 4 Gys (total of 8 Gys) starting 1 week after Imiquimoid course over 2 days.

Locations

Country	Name	City	State
United States	Northwestern University Department of Dermatology	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
Northwestern University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of a combination local radiotherapy and topical imiquimod approach for the treatment of conventional (CD4+) MF as measured by mSWAT at week 8.	The primary efficacy endpoint will be skin disease response as measured by mSWAT (Modified Severity-Weighted Assessment Tool) at week 8.	8 weeks
Primary	Incidence of treatment-emergent adverse events (safety and tolerability) of a combination local radiotherapy and topical imiquimod approach for the treatment of conventional (CD4+) MF.	Adverse event occurrence during study.	12 weeks
Secondary	Microbiome alterations before and after treatment	To measure alterations in lesional (tumor-associated) skin, nasal, and gut microbiomes before and after combination RT/imiquimod treatment and associate these differences in microbiomes with clinical response (and any toxicity). Differences in microbiome bacterial species will be measured by alpha and beta diversity metrics. Alpha diversity quantifies within sample diversity. Beta diversity compares between sample diversity (before and after treatment).	12 weeks
Secondary	Tumor-associated and serum immune alterations before and after treatment	To correlate quantitative changes in tumor-associated and serum immune response profiles with clinical response to RT/imiquimod treatment (and any toxicity).	12 weeks